Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1Dermatologic 1

Conditions

Breast Neoplasms 4Neoplasms 2Somatostatinoma 1Prostatic Neoplasms 1Pituitary Neoplasms 1Pancreatic Neoplasms 1Pain 1Lymphoma, Mantle-Cell 1Hematologic Neoplasms 1Hematologic Diseases 1Growth Hormone-Secreting Pituitary Adenoma 1Colonic Neoplasms 1Carcinoma, Neuroendocrine 1Carcinoma, Merkel Cell 1Carcinoma, Islet Cell 1Barrett Esophagus 1

Interventions

Capecitabine 6Temozolomide 5Octreotide 4Leucovorin 4Everolimus 4Fluorouracil 3Bevacizumab 3vatalanib 2pentetreotide 2Trastuzumab 2Sunitinib 2Oxaliplatin 2Magnetic Resonance Spectroscopy 2Cisplatin 2Bortezomib 2Biological Therapy 2veliparib 1tipifarnib 1temsirolimus 1sapanisertib 1romidepsin 1regorafenib 1pazopanib 1palbociclib 1motesanib diphosphate 1lutetium Lu 177 dotatate 1irinotecan sucrosofate 1gallium Ga 68 dotatate 1dehydroftorafur 1cixutumumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Somatostatinoma × Complementary Therapies × Clear all
NCT00003514 2013-07-10

Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy

National Cancer Institute (NCI)

Phase 2 Withdrawn
DermatologicEndocrine

Pituitary Neoplasms, Somatostatinoma, Carcinoma, Merkel Cell, Carcinoma, Islet Cell, Carcinoma, Neuroendocrine, Growth Hormone-Secreting Pituitary Adenoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡